Clinical Trials
15
Active:0
Completed:15
Trial Phases
3 Phases
Phase 1:7
Phase 2:3
Phase 3:5
Drug Approvals
1
EMA:1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (15 trials with phase data)β’ Click on a phase to view related trials
Phase 1
7 (46.7%)Phase 3
5 (33.3%)Phase 2
3 (20.0%)Estetrol for the Treatment of Female Sexual Arousal Disorder in Postmenopausal Women
Phase 2
Completed
- Conditions
- Sexual Dysfunction, Physiological
- Interventions
- Drug: 20 mg estetrol monohydrateOther: Placebo
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2025-09-03
- Lead Sponsor
- Estetra
- Target Recruit Count
- 82
- Registration Number
- NCT06308614
- Locations
- πΊπΈ
Estetra Study Site, Seattle, Washington, United States
Effect of Estetrol Monohydrate (E4) on QTc Interval
Phase 1
Completed
- Conditions
- Prolonged QTc Interval
- Interventions
- First Posted Date
- 2021-03-29
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Estetra
- Target Recruit Count
- 32
- Registration Number
- NCT04819906
- Locations
- πΊπΈ
QPS Miami, Miami, Florida, United States
Safety, Compliance and Pharmacokinetics of Estetrol Monohydrate/Drospirenone 15/3 mg in Post-menarchal Female Adolescents
Phase 3
Completed
- Conditions
- Safety
- Interventions
- Drug: E4/DRSP 15/3 mg combined tablet
- First Posted Date
- 2021-03-11
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- Estetra
- Target Recruit Count
- 145
- Registration Number
- NCT04792385
- Locations
- πͺπͺ
KVL Medical Office/KVL Arstikabinet, Parnu, Estonia
πͺπͺEast-Tallinn Central Hospital, Tallinn, Estonia
πͺπͺSexual Health Clinic, Tallinn, Tallinn, Estonia
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)
Phase 3
Completed
- Conditions
- Vasomotor SymptomsMenopausal Symptoms
- Interventions
- First Posted Date
- 2019-12-24
- Last Posted Date
- 2025-01-29
- Lead Sponsor
- Estetra
- Target Recruit Count
- 1570
- Registration Number
- NCT04209543
- Locations
- π¬π§
Estetra Study Site, Orpington, United Kingdom
πΊπΈPrecision Trials AZ, LLC, Phoenix, Arizona, United States
πΊπΈNoble Clinical Research, Tucson, Arizona, United States
Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women
Phase 3
Completed
- Conditions
- Vasomotor SymptomsMenopausal Symptoms
- Interventions
- Drug: Placebo oral tablet
- First Posted Date
- 2019-09-16
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Estetra
- Target Recruit Count
- 1015
- Registration Number
- NCT04090957
- Locations
- π¨π¦
Estetra Study Site, Waterloo, Canada
- Prev
- 1
- 2
- 3
- Next
News
No news found